The End of Toxoid Vaccine Development for Preventing Clostridioides difficile Infections?
- PMID: 39178347
- DOI: 10.1093/cid/ciae412
The End of Toxoid Vaccine Development for Preventing Clostridioides difficile Infections?
Keywords: Clostridioides difficile; CLOVER trial; vaccination.
Conflict of interest statement
Potential conflicts of interest. D. N. G. received consulting fees from Destiny Farma, Sebela Pharma, and AstraZeneca. Leiden University Medical Centre (LUMC) received consulting fees for E. J. K. from Janssen Vaccines and Prevention, and from Wellcome Trust. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.Clin Infect Dis. 2024 Dec 17;79(6):1503-1511. doi: 10.1093/cid/ciae410. Clin Infect Dis. 2024. PMID: 39180325 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources